Literature DB >> 25964581

The prognostic role of claudins -1 and -4 in oral squamous cell carcinoma.

Juan C DE Vicente1, Álvaro Fernández-Valle2, Blanca Vivanco-Allende3, Tania Rodríguez Santamarta2, Paloma Lequerica-Fernández4, Gonzalo Hernández-Vallejo5, Eva Allonca-Campa3.   

Abstract

Claudin dysregulation has been described in various tumor types; however, its clinical relevance is poorly understood. We present a study in which we assessed the expression of claudin 1 (CLDN1) and CLDN4 in oral squamous cell carcinoma (OSCC), as well as their prognostic relevance. Immunohistochemical analysis of CLDN1 and CLDN4 expression was carried out on tissue sections from 65 OSCCs. The presence of CLDN1 in the invasive front of tumor islands was associated with neck node metastasis, and the expression of CLDN4 was associated with higher histological grade, and tumor recurrence. Membranous staining for CLDN4 in tumor cells, and weak intensity of CLDN4 immunoexpression were predictive for poorer survival. In a multivariate analysis for disease recurrence, CLDN1 immunostaining was statistically significant. Specifically, CDLN1 expression in the tumor invasive front was associated with tumor recurrence. Our results indicate that CLDN4 expression is correlated with poor prognosis, and CLDN1 expression may be an indicator of recurrence of OSCC. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Claudin 1; claudin 4; immunohistochemistry; oral squamous cell carcinoma; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25964581

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Altered expression of junctional proteins as a potential biomarker in oral precancerous and cancerous patients.

Authors:  Puja Upadhaya; Sarbani Giri; Dharmeswar Barhoi; Abhinandan Bhattacharjee
Journal:  Tissue Barriers       Date:  2021-09-17

2.  Expression of Claudin-1 in laryngeal squamous cell carcinomas (LSCCs) and its significance.

Authors:  Abderrahman Ouban
Journal:  Histol Histopathol       Date:  2021-02-25       Impact factor: 2.303

3.  Interobserver Variation Among Pathologists in Evaluating Perineural Invasion for Oral Squamous Cell Carcinoma.

Authors:  Angela C Chi; Nora Katabi; Huey-Shys Chen; Yi-Shing Lisa Cheng
Journal:  Head Neck Pathol       Date:  2016-05-02

4.  Claudin1 promotes the proliferation, invasion and migration of nasopharyngeal carcinoma cells by upregulating the expression and nuclear entry of β-catenin.

Authors:  Xin Wu; Jianghong Xiao; Chong Zhao; Chengjian Zhao; Zhongcheng Han; Feng Wang; Yuqiong Yang; Yu Jiang; Fang Fang
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447

5.  Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients.

Authors:  Aimin Hu; Junyu Li; Shufang Ruan; Ying Fan; Yuqian Liao
Journal:  Biosci Rep       Date:  2019-04-23       Impact factor: 3.840

6.  Clinical Significance of Claudin Expression in Oral Squamous Cell Carcinoma.

Authors:  Tatjana Zejc; Jörg Piontek; Jörg-Dieter Schulzke; Michael Fromm; Jürgen Ervens; Rita Rosenthal
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

7.  Analysis of the distribution and expression of some tumor invasiveness markers in palate squamous cell carcinomas.

Authors:  Adrian Pătru; Valeriu Şurlin; Claudiu Mărgăritescu; Eduard Mihai Ciucă; Marius Matei; Mircea Sebastian Şerbănescu; Adrian Camen
Journal:  Rom J Morphol Embryol       Date:  2020 Oct-Dec       Impact factor: 0.833

Review 8.  Claudin-1, A Double-Edged Sword in Cancer.

Authors:  Ajaz A Bhat; Najeeb Syed; Lubna Therachiyil; Sabah Nisar; Sheema Hashem; Muzafar A Macha; Santosh K Yadav; Roopesh Krishnankutty; Shanmugakonar Muralitharan; Hamda Al-Naemi; Puneet Bagga; Ravinder Reddy; Punita Dhawan; Anthony Akobeng; Shahab Uddin; Michael P Frenneaux; Wael El-Rifai; Mohammad Haris
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.